A Phase II Study Evaluating the Efficacy and Safety of Bortezomib (Velcade™) Combined With ACVBP Regimen in Patients With Previously Untreated Peripheral T-cell Lymphoma
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2018
At a glance
- Drugs Bortezomib (Primary) ; Bleomycin; Cyclophosphamide; Doxorubicin; Prednisone; Vindesine
- Indications T cell lymphoma
- Focus Therapeutic Use
- 21 Aug 2018 Status changed from active, no longer recruiting to completed.
- 07 Nov 2007 Additional lead trial center and investigators identified as reported by ClinicalTrials.gov.
- 06 Oct 2006 Status change